- Home
- MGRX vs TOVX Comparison
MGRX vs TOVX Comparison
Compare MGRX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGRX | TOVX |
|---|---|---|
| Founded | 2021 | 2001 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 6.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MGRX | TOVX |
|---|---|---|
| Price | $0.38 | $0.18 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 355.7K | ★ 1.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.17 |
| 52 Week High | $6.15 | $1.75 |
Technical Indicators
Market Signals| Indicator | MGRX | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 33.55 | 44.84 |
| Support Level | $0.36 | $0.18 |
| Resistance Level | $0.45 | $0.21 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 26.56 | 28.00 |
Price Performance
Historical ComparisonAbout MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.